Business Wire

RECORDATI-RARE-DISEASES

17.6.2020 10:00:09 CEST | Business Wire | Press release

Share
Recordati Rare Diseases: Isturisa® (osilodrostat) Phase III LINC-4 Trial Meets Its Primary Endpoint in Cushing’s Disease

Recordati Rare Diseases today announces positive results from the large Phase III LINC-4 study of Isturisa® (osilodrostat) for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative. Data from the LINC-4 study demonstrate that a significantly higher proportion of patients receiving Isturisa® achieve normal mUFC, the primary treatment goal for Cushing’s disease, after 12 weeks of treatment versus placebo (77% vs 8%; P <0.0001). Improvements in mUFC levels are sustained over 36 weeks of treatment (81% of patients). Isturisa® is well tolerated and has a manageable safety profile, with the most common adverse events in LINC-4 being arthralgia, decreased appetite, fatigue, and nausea. The findings from LINC-4, the first Phase III study of a medical therapy in Cushing’s disease to contain an upfront placebo-controlled phase, builds upon existing clinical evidence and affirms the effectiveness of Isturisa® in this hard-to-treat patient population.1-3

“Cushing’s disease is a chronic and debilitating condition that can be extremely challenging to manage and, if left inadequately treated, can have a significant impact on patients’ quality of life and increase the risk of mortality”, said Richard Feelders, MD, Professor of Endocrinology at the Erasmus University Medical Centre, Rotterdam. “Data from this important Phase III study show that Isturisa® (osilodrostat) is an effective and well-tolerated therapy for Cushing’s disease, which significantly reduces and normalizes mUFC levels in most patients. These data are encouraging given the high unmet medical need for patients with this rare disorder”.

“The compelling topline LINC-4 data confirm the effectiveness of Isturisa® for the treatment of this rare, potentially life-threatening disease”, stated Andrea Recordati, CEO. “We are deeply grateful to the patients, investigators, clinicians and study staff whose ongoing participation in the clinical development of Isturisa® has helped bring this therapy to patients in need.”

Data from the LINC 4 study reinforce the clinical benefits of Isturisa® as an effective and generally well‑tolerated oral treatment option for patients with Cushing’s disease.

About Cushing’s syndrome

Cushing’s syndrome is caused by an inappropriate and chronic exposure to excessive levels of cortisol. The source of this excess of cortisol can be endogenous or exogenous (ie medication). When the excess cortisol production is triggered by a pituitary adenoma (ie a tumor of the pituitary gland located in the brain) secreting excess adrenocorticotropic hormone (ACTH), the condition of the patient is defined as Cushing’s disease and comprises about 70% of Cushing’s syndrome cases.4 It is a rare, serious and difficult-to-treat disease that affects approximately one to two patients per million per year.5 Prolonged exposure to elevated cortisol levels is associated with considerable morbidity, mortality and impaired quality of life as a result of complications and comorbidities.6 Normalization of cortisol levels is therefore a primary objective in the treatment of Cushing’s syndrome.7

About LINC-4

LINC-4 is a large randomized, double-blinded, multicentre, 48-week trial with an initial 12-week placebo-controlled period to evaluate the safety and efficacy of osilodrostat in patients with Cushing’s disease. The primary endpoint in the LINC-4 trial is the proportion of patients randomized to Isturisa® and placebo, separately, with a mUFC ≤ULN at the end of the 12-week placebo-controlled period. The key secondary endpoint is the proportion of patients in both arms combined with a mUFC ≤ULN after 36 weeks. LINC-4 involved 73 patients with persistent or recurrent Cushing’s disease or those with de novo disease who were not candidates for surgery.

About Isturisa®

Isturisa® is a potent oral inhibitor of 11β-­hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol synthesis in the adrenal gland. Isturisa® will be available as 1-mg, 5-mg and 10-mg film-coated tablets. Isturisa®, indicated for the treatment of adult patients with endogenous Cushing’s syndrome (CS), is now available in France as the first EU country to launch. Isturisa® was granted marketing authorization by the European Commission (EC) on 9 January 2020. Please see prescribing information for detailed recommendations for the use of this product.8

References

  1. Bertagna X et al. J Clin Endocrinol Metab 2014;99:1375–83
  2. Fleseriu M et al. Pituitary 2016;19:138–48
  3. Biller BMK et al. Abstract OR16-2. Oral presentation at the Endocrine Society Annual Congress 2019
  4. Nieman LK et al. Am J Med 2005;118:1340
  5. Signifor® and Signifor® LAR Summary of Product Characteristics, June 2018
  6. Pivonello R et al. Lancet Diabetes Endocrinol 2016;4:611–29
  7. Nieman LK et al. J Clin Endocrinol Metab 2015;100:2807–31
  8. Isturisa® Summary of Product Characteristics, May 2020

About Recordati Rare Diseases

The company’s EMEA headquarters is located in Puteaux, France, with global headquarter offices located in Milan, Italy.

For a full list of products, please click here: www.recordatirarediseases.com/products .

For additional information, please visit our websites: www.recordati.com and https://www.recordatirarediseases.com/ or follow us on LinkedIn or Twitter for company updates.

About the Recordati group

Recordati , established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations throughout the whole of Europe, including Russia, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2019 was € 1,481.8 million, operating income was € 465.3 million and net income was € 368.9 million.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

Frontgrade Technologies Help Power Critical Computing and Electronics Aboard NASA’s Roman Space Telescope20.11.2026 18:40:00 CET | Press release

Frontgrade processors and radiation-hardened microelectronics support critical spacecraft and instrument functions on NASA’s flagship astrophysics mission Frontgrade today announced that technologies from across its space electronics portfolio are supporting multiple mission-critical systems aboard NASA’s Nancy Grace Roman Space Telescope, which successfully launched on August 30, 2026. Roman is NASA’s flagship astrophysics observatory designed to investigate dark energy, discover exoplanets and explore the evolution of the universe. Its onboard electronics include radiation-hardened processors and microelectronics, providing critical processing, communications, power-management and control functions across the spacecraft. At the centre of Roman’s computing architecture are Frontgrade Gaisler’s GR740 and GR712RC processors. The GR740 radiation-hardened quad-core LEON4FT processor serves as the computing engine for the Wildcat Processor Card, used in the spacecraft’s primary and redunda

Inside Moutai House Singapore: Beyond Baijiu, A Cultural Encounter20.11.2026 16:05:00 CET | Press release

On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120301288/en/ On November 13, Moutai House officially opened at Fullerton Waterboat House in Singapore. As the world’s first Moutai brand experience space built under its new SI standards, this three-storey venue brings together cultural exhibitions, baijiu tasting, distinctive dining and creative cocktails. Using Moutai as a bridge, it creates new opportunities for Chinese baijiu culture to blend with and draw inspiration from Singapore’s diverse lifestyle and cultural scene. As early as 1954, Guizhou Moutai arrived in Singapore via the Singapore River, marking its first entry into Southeast Asia, right across from Fullerton Waterboat House. 72 years later, Moutai House has found its home along the same riverbank, transforming a historic arrival into a lasting presence and turning a con

ViTAA Medical and The Society for Vascular Surgery Announce Strategic Partnership20.11.2026 15:00:00 CET | Press release

ViTAA Medical to Become Key SVS AI Partner, Advancing AI Education and Responsible Adoption in Vascular Care ViTAA Medical Solutions Inc. (ViTAA) today announced a strategic partnership with The Society for Vascular Surgery (SVS) to advance evidence, education, and the responsible adoption of quantitative imaging and artificial intelligence in vascular care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120954362/en/ The partnership will support evidence building, best practices, educational resources for SVS members, physicians and trainees on AI validation, interpretation, and clinical limitations. The relationship has the potential to pave the way for additional AI tools and resources for SVS members through the Society in the future. The partnership creates a framework for the organizations to lead AI-enabled research opportunities involving imaging and clinical outcomes. Mitchel Benovoy, PhD, Chief Executive Officer

Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health20.11.2026 14:39:00 CET | Press release

Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approaches to address unmet medical needs in eye health. A combination of complementary scientific expertise Epitech Group has been studying ALIAmides and their role in physiological regulatory mechanisms for over 30 years, building on the research of Rita Levi-Montalcini, the 1986 Nobel Prize in Medicine laureate who first identified the ALIA mechanism. Horus Pharma, for its part, contributes over 20 years of ophthalmology expertise, strong R&D capabilities, and its international presence. Against the backdrop of an aging population

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye